Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vaginal estrogen may ease bladder troubles by altering urine microbiome

NCT ID NCT06780163

Symptom relief Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a low-dose vaginal estrogen tablet could improve overactive bladder symptoms in menopausal women by changing the bacteria in their urine. Thirty women used the tablet daily for two weeks, then twice a week for 12 weeks. Researchers measured changes in Lactobacillus levels and other urine bacteria, and linked those changes to symptom improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

30 people

The number who actually took part.

Started

Jun 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Natural or surgical menopause at least 1 year * Present with overactive bladder symptoms by using validated Thai version of OVERACTIVE BLADDER SYMPTOM SCORE (score in No.3 ≥ 2 and overall score ≥ 3) * Absence of urinary infection * Post-void residual urine less than 100ml Exclusion Criteria: * Currently or prior use of systemic hormone replacement therapy or vaginal estrogen within the past 3 months * Contraindication or allergy to estrogen therapy * Use of antibiotics, prebiotics and probiotics within the past 2 weeks * Currently on antimuscarinic or β3 agonists medication or within the past 3 months * Pelvic organ prolapse greater than stage II

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopause are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Menopause Microbiome Overactive bladder (OAB)

Contacts and locations

Locations

  • Faculty of Medicine Ramathibodi Hospital, Mahidol University

    Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.